 | Up a level |
Journal Article
Ludwig, Saskia and Dintsios, Charalabos-Markos 
ORCID: 0000-0003-3469-092X
(2016).
Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience.
Value Health, 19 (8).
S. 1016 - 1026.
NEW YORK:
ELSEVIER SCIENCE INC.
ISSN 1524-4733
Mueller, Dirk, Stock, Stephanie ORCID: 0000-0002-1726-9300, Dintsios, Charalabos-Markos ORCID: 0000-0003-3469-092X, Chernyak, Nadja, Gerber-Grote, Andreas ORCID: 0000-0003-2157-4065, Gloede, Tristan Daniel, Hermann, Benita, Huppertz, Eduard, Juelich, Fabian, Mostardt, Sarah, Köberlein-Neu, Juliane ORCID: 0000-0002-3451-7847, Prenzler, Anne, Salize, Hans-Joachim, Santos, Sara, Scheckel, Benjamin, Seidl, Astrid, Wahlers, Katharina and Icks, Andrea
(2018).
Checklist for the Development and Assessment of Cost-of-Illness Studies.
Gesundheitswesen, 80 (8-9).
S. 744 - 754.
STUTTGART:
GEORG THIEME VERLAG KG.
ISSN 1439-4421
Niehaus, Ines Marina ORCID: 0000-0002-4214-6898 and Dintsios, Charalabos-Markos ORCID: 0000-0003-3469-092X
(2018).
Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs.
Health Policy, 122 (6).
S. 599 - 607.
CLARE:
ELSEVIER IRELAND LTD.
ISSN 1872-6054